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Abstract
Background (1) To determine the optimal administration
site and dose of indocyanine green (ICG) for blood volume
measurement using pulse spectrophotometry, (2) to assess
the variation in repeated blood volume measurements for
patients after subarachnoid hemorrhage and (3) to evaluate
the safety and efficacy of this technique in patients who
were treated for an intracranial aneurysm.
Methods Four repeated measurements of blood volume
(BV) were performed in random order of bolus dose (10 mg
or 25 mg ICG) and venous administration site (peripheral or
central) in eight patients admitted for treatment of an
intracranial aneurysm. Another five patients with subarach-
noid hemorrhage underwent three repeated BV measure-
ments with 25 mg ICG at the same administration site to
assess the coefficient of variation.
Findings The mean ± SD in BV was 4.38 ± 0.88 l (n=25)
and 4.69 ± 1.11 l (n=26) for 10 mg and 25 mg ICG,
respectively. The mean ± SD in BV was 4.59 ± 1.15 l (n=
26) and 4.48 ± 0.86 l (n=25) for central and peripheral
administration, respectively. No significant difference was
found. The coefficient of variance of BV measurement with
25 mg of ICG was 7.5% (95% CI: 3–12%).
Conclusions There is no significant difference between
intravenous administration of either 10 or 25 mg ICG, and
this can be injected through either a peripheral or central
venous catheter. The 7.5% coefficient of variation in BV
measurements determines the detectable differences using
ICG pulse spectrophotometry.
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Introduction
The majority of patients with an aneurysmal subarachnoid
hemorrhage (SAH) have a poor prognosis, with mortality
rates as high as 45% and significant morbidity among the
survivors [1]. The major causes of morbidity are the initial
bleed, a rebleed, hydrocephalus and delayed ischemic
neurological deficits (DIND). Delayed ischemic neurological
deficits (DIND) are presumably related to cerebral vaso-
spasm and have a large impact on outcome after SAH [3, 17,
18]. This ischemic complication occurs in 17–40% and
carries a risk of 10–20% of permanent disability or death
[12, 18]. A hallmark of current therapy includes induction of
hypervolemia, hemodilution and hypertension (triple-H
therapy) aiming to restore cerebral perfusion [12]. This
aggressive treatment is controversial, however, and its
efficacy has not been proven in prospective studies.
Additionally, it has considerable morbidity, such as pulmo-
nary edema and cardiac failure [4, 12]. In a recent study
performed by Hoff et al. [7], no association between daily or
cumulative fluid balance and actual circulating blood volume
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was seen. So, to increase therapeutic efficacy of triple-H
therapy and decrease morbidity, monitoring of circulating
blood volume (BV) prior to and during treatment for
symptomatic cerebral vasospasm may be of value [11, 16].
Blood volume can be determined using dye dilution [5, 9].
Determination of BV using indocyanine green (ICG)
administration and detection with pulse spectrophotometry
has several advantages. It can be performed in several
minutes at the bedside [5, 10, 15], allowing multiple
measurements on a daily basis, limited only by the short
washout time of the ICG dye [2]. This technique has been
validated in healthy volunteers and is comparable in accuracy
to the gold standard isotopic dilution techniques [6, 8].
Furthermore, ICG pulse spectrophotometry has been safely
applied in critically ill patients in the ICU and perioperatively
[9, 13, 14]. In our opinion, this technique could be used to
optimize the BV status of patients after SAH. However, for
the reliable clinical application of this technique in patients
with intracranial pathology, several issues need to be
addressed. First, the optimal ICG dose site of venous
administration (central vs. peripheral) has to be determined,
and second, the variation in repeated BV measurements
should be assessed to determine the detectable differences.
The aims of this study were (1) to determine the optimal
dose and venous administration site for ICG for measure-
ment of BV, (2) to establish the coefficient of variation for
repeated BV measurements with pulse spectrophotometry
and (3) to evaluate the safety and efficacy of this technique
in patients who were treated for an intracranial aneurysm.
Methods and materials
Patient population
Adult patients (≥18 years) admitted for treatment of an
intracranial aneurysm, with or without recent subarachnoid
hemorrhage (confirmed on computer tomography scan or by
lumbar puncture positive for xanthochromia), were recruited
for this study. All patients had a medical indication for both a
central and a peripheral venous catheter and were admitted to
the intensive care. Exclusion criteria were iodine allergy or
increased baseline liver enzymes (AST > 150 U/l or ALT >
150 U/l or AF > 150 U/l or γ-GT > 150 U/l) because ICG is
cleared hepatically. The Medical Ethical Committee of the
University of Amsterdam approved the study protocol (02/
203 no. 02.17.1017), and informed consent was obtained from
all participants.
Indocyanine green dilution procedure
The Dye Densitogram 2501 A/K analyzer (Nihon Kohden,
Tokyo, Japan) was used for registration of the spectrophoto-
metrical absorption of ICG and calculation of the BV. After an
intravenous bolus of ICG (Infracyanine®, S.E.R.B. laborato-
ries pharmaceutiques, Paris, France) in glucose 5% solution,
the decay curve in the peripheral tissue was assessed
spectrophotometrically with a light probe attached to the nasal
wing for 10min. Because ICG does not leave the intravascular
compartment, the diluting volume for ICG equals the BV. The
diluting volume can be calculated from the decay curve by
regression [5], and measurements can be repeated after
30 min when all ICG has been cleared by the liver [6].
Further details have been described elsewhere [8, 9].
Study protocol
In this study two successive protocols were used. The first
was to determine the optimal dose and administration site,
followed by the establishment of the coefficient of
variation.
In the first protocol, ICG powder was dissolved in glucose
5% to a concentration of 5 mg/ml, from which either 5 ml
(25 mg ICG) or 2 ml (10 mg ICG) was used as bolus. The
bolus was manually infused within 5 s through either a
peripheral or central venous catheter followed by 20 ml or
23 ml glucose 5% flush, respectively. Using the pulse
spectrophotometer probe attached to the nasal wing, dye
absorption was instantaneously measured for the following
10 min. All patients received every single combination
between dose and administration site with 30-min intervals.
The order of combinations was randomized in advance.
The four measurements consisted of two paired observa-
tions of 10 mg ICG versus 25 mg ICG and two paired
observations of central versus peripheral venous administra-
tion site. Patients who were eligible for more than one series
of four repeated measurements participated to a maximum of
three separated series. Because of the admission of 25 ml of
the study agent in four repeated BV measurements reduced
by continuous diuresis, the net result in fluid balance was
assumed to be constant during the experiment.
To determine the coefficient of variance, three repeated
BV measurements using 25 mg ICG through the same
venous administration site were performed in a period with
30-min intervals. For this protocol, five different patients
with recent SAH were included who had not participated in
the first part of this study.
Statistics
The BV difference between low- and high-dose ICG and
between central and peripheral venous administration was
hypothesized to be less than 5%. Assuming a standard
deviation of 5%, a power of 0.90 and an α-level of 0.05, a
minimum of 23 paired observations were required. A linear
mixed model was used to establish differences in BV
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between low and high dose ICG and central and peripheral
administration site.
Data analysis was performed using SPSS 16.0.1 (SPSS
Inc, Chicago, IL) with the restricted maximum likelihood
estimation method using BV as independent variable. ICG
dose, administration site and the interaction of these were
included as fixed effects, and patient and repeated mea-
surement series identification as random effects.
Results
The first study population consisted of two males and six
females with a mean age of 46.4 ± 9.8 years. Seven patients
presented with a ruptured aneurysm and one with an
incidental aneurysm discovered by computer tomography
angiography. Five aneurysms were situated in the anterior
circulation, and there were two posterior communicating
artery and one posterior inferior cerebellar artery aneurysms;
all were treated surgically. Three patients had been treated
for DIND with triple-H therapy, and during the repeated BV
measurements none of the patients was suspected of having
symptomatic cerebral vasospasm, evaluated by neurological
examination. Two patients had a mild hyponatriaemia (130–
135 mmol/l) during measurements; these had not been
previously treated with triple-H therapy (see Table 1).
In 8 patients, 51 BV measurements were done resulting in
25 paired observations. One patient completed three series of
the four repeated measurements on separate days, three
patients completed two series, and four patients completed
one series. An ICG dose of 10mg and 25mgwas administered
in 25 and 26 measurements, respectively. A central venous
catheter and a peripheral venous catheter were used for
administration in respectively 26 and 25 measurements. One
Table 1 Patients characteristics and interval between hemorrhage and BV measurement of first study population (see text)
Patient Gender Age
(years)
Weights
(kgs)
Hunt and
Hess
Localisation of
aneurysm
Treatment Triple-H Hyponatriaemia Days between SAH
and measurement(s)
1 F 40 62.0 I ACM Clip Yes No 10
2 M 39 70.0 0 PICA Clip No No n.a.
3 F 41 70.0 II P.comm. Clip No Yes 3
4 F 42 60.0 III ACM Clip Yes No (1) 21
(2) 22
5 F 54 79.0 II ACM Clip No No (1) 2
(2) 3
(3) 6
6 F 66 66.0 III P.comm. Clip No Yes (1) 15
(2) 16
7 M 51 80.0 II Ant.chor. Clip Yes No (1) 7
(2) 8
8 F 38 60.0 II ACM Clip No No 36
ACM: middle cerebral artery; PICA: posterior inferior cerebellar artery; p.comm.: posterior communicating artery; Ant.chor.: anterior choroideal
artery
Fig. 1 Results of blood volume
measurements. On x-axis
the combination of dose and site
administration with means ±
standard deviation: 1= central
10 mg: 4.28 ± 0.94 l (n=13);
2= central 25 mg: 4.90 ±
1.28 l (n=13); 3= peripheral
10 mg: 4.49 ± 0.84 l (n=12);
4= peripheral 25 mg: 4.47 ±
0.91 l (n=13)
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measurement of 10 mg ICG bolus through a peripheral venous
catheter was not completed, because the patient withdrew from
further participation due to pain at the injection site at bolus
injection. No other adverse events were observed.
The mean ± SD of the BV measured by 10 mg and 25 mg
ICG was 4.38 ± 0.88 l (n=25) and 4.69 ± 1.11 l (n=26),
respectively. At central and peripheral administration, it was
4.59 ± 1.15 l (n=26) and 4.48 ± 0.86 l (n=25), respectively
(Fig. 1). Using the linear mixed model, we calculated
comparable BVs in the two sites of administration (esti-
mate=0.43 l, SE=0.27, p=0.126), as well in the two
different doses (estimate=0.02 l, SE=0.28, p=0.953). With
these results we could not determine a significant difference
between the ICG dose nor the administration site.
Subsequently, the coefficient of variance was measured
in three repeated BV measurements in five patients, two
females and three males with a mean age of 64 ± 9 years
(patients a to e; see Table 2). Calculated BVs of the three
measurements in every patient (a to e) are plotted in Fig. 2.
The mean ± SD of the coefficient of variation for a 25 mg
ICG bolus in five patients was 7.5% ± 3.6% resulting in a
95% CI between 3% and 12%.
Discussion
For determination of BV by ICG pulse spectrophotometry in
patients being treated for an intracranial aneurysm, there is no
significant difference between a bolus ICG dose of 10 or
25 mg through either a central or peripheral venous catheter.
Earlier reports using ICG spectrophotometry in critically ill
patients describe varying dosages of ICG between 10 and
25 mg [5, 6, 8–11, 14, 15]. It seems reasonable to use a
standardized ICG bolus dose; in the calculation for variance,
we have chosen 25mg to minimize the error of spilling ICG at
injection. As can be concluded from these data, the theoretical
delay to mean transit time from peripheral injection does not
substantially affect BV measurements in adult patients with
average weight. This is in contrast with He et al. [6], who
suggested that the mean transit time depends on the size of
the subject. As they drew their conclusion after comparison
between adults and children with diverse body surface areas,
no conclusive statement can be made concerning this issue.
When evaluating the larger than average BV measure-
ments, no direct relation was seen between previous triple-
H therapy or hyponatriemia during the measurement except
for one patient. His BV was larger than the standard
deviation in three of four measurements, explained by the
preceded triple-H therapy 2 days before. The absence of a
relation is in accordance with the conclusion of a recent
study of Hoff et al. [7] who “…raises doubt whether fluid
management guided by fluid balances is effective….”
During the inclusion period also one patient without a
recent SAH was treated. Theoretically, this could confound
the results because BV in a presumed healthy patient could
be different as compared with patients with a recent SAH.
But in our opinion, measurements in this patient did not
influence the results because treatment of this patient was
identical to patients with SAH and an uncomplicated course.
With the standard 25-mg dose injected through either
venous administration site, the coefficient of variance of BV
measurements appears to be 7.5%. Taking the 95% confidence
Table 2 Patients characteristics and interval between hemorrhage and BV measurement of second study population (see text)
Patient Gender Age
(years)
Hunt and Hess Localisation Treatment Triple-H Hyponatriaemia Days between SAH
and measurements
a F 74 II P.comm. Clip No No 11
b M 70 II - - No No 7
c M 61 I A.comm. Coil No Yes 13
d F 69 III A.comm. Clip Yes Yes 22
e M 57 II Bas.top Coil No No 6
ACM: middle cerebral artery; PICA: posterior inferior cerebellar artery; p.comm.: posterior communicating artery; a.comm.: anterior
communicating artery
Fig. 2 Repeated blood volume measurements in separate patients
(a to e) with 25 mg ICG through the same administration site
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interval into account, it seems reasonable to assume that the
mean differences in BV of more than 12% can be detected
significantly using this technique. This percentage is an
important baseline parameter for planning further studies.
One study using repeated BV measurements with ICG
pulse spectrophotometry in healthy volunteers determined a
variation of 3.94% [6]. The larger variation in our data can
be explained by the different measurement circumstances
and smaller number of patients. The measurements in our
study were performed when the patient was awake, contrary
to the patients who were under general anesthesia in the
study of He et al. Apparently, awake patients induce more
measurement artifacts, probably by probe movement or
changes in cardiac output during the 10-min pulse spectro-
photometry or between successive measurements. Neverthe-
less, our results show that reliable BV measurements can
also be performed in awake patients with recent SAH.
Our percentage of coefficient of variance is an important
baseline parameter for planning further studies concerning
patients with SAH.
Blood volume can be determined in a safe and
reproducible manner in patients after SAH using ICG pulse
spectrophotometry. Administration of a bolus of either 10
or 25 mg ICG through a central or peripheral catheter
results in no significant differences in measured BV. To
minimize the error of spilling during injection, we
recommend 25-mg boluses for repeated BV measurements.
The coefficient of variation of repeated measurements with
25 mg is estimated at 7.5%. These results are considered
important premises for planning further clinical studies.
Open Access This article is distributed under the terms of the
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Comment
The authors provide a means for easy and consistent measurement of BV
in patients with SAH. The further perspective is to validate in due time the
use of triple-H therapy in these patients by having a measurement tool to
know whether “volume” interventions really do increase circulating
blood volume. The authors have adopted an existing technique and have
standardized this in a sensible matter: one place for infusion of dye, one
concentration for all. The results prove rather adequately that this is
possible. The neurosurgical community will look forward to further
studies with the use of this technique that may prove or disprove that
“single-,” “double-” or “triple”-H therapy has a physiological basis and
effect in the treatment of secondary ischemia after SAH!
J.J.A. Mooij
Groningen, The Netherlands
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